MedTrace Logo

Antireflux Ablation of the Cardia Mucosa vs Placebo for the Treatment of Gastroesophageal Reflux Disease

NCT04711655 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2025-04-24

No results posted yet for this study

Summary

The ARMA technique improves GORD-related quality of life with a low proportion of adverse effects.

Conditions

  • Gastroesophageal Reflux Disease

Interventions

PROCEDURE

ARMA (antireflux ablation of the cardiac mucosa)

is an endoscopy in which argon gas ablation of the cardiac mucosa

PROCEDURE

upper digestive endoscopy

Quality diagnostic upper gastrointestinal endoscopy will be performed without intervention in patients assigned to this treatment arm.

Sponsors & Collaborators

  • Spanish Society of Digestive Endoscopy

    collaborator OTHER

  • Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

    lead OTHER

Principal Investigators

  • Enrique MD Rodríguez de Santiago · Servicio de Gastroenterología y Hepatología Hospital Ramón y Cajal

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2023-12-31
Completion
2025-02-07

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04711655 on ClinicalTrials.gov